Jesse Anderson Corley
Known title: DirectorCIK: 0001874878
Jesse Anderson Corley's purchase track record
How the stock did after each of Jesse Anderson Corley's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since November 17, 2021
Stock higher 6 months later
0%
3 months: 33%
Median 6-month return
-71.0%
3 months: -29.2%
Beat the S&P 500
33%
median -69.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/15/2025 | RXST | $100K | -53.6% | -76.8% | +5.3% |
| 11/12/2024 | RXST | $1.01M | -29.2% | -71.0% | -1.6% |
| 11/17/2021 | RXST | $102K | +8.9% | -1.7% | -16.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RXST | ▲ Buy | Grant | 37,037 | — | 6/17/2026 | View on chart |
| RXST | ▲ Buy | Grant | 10,752 | — | 6/3/2025 | View on chart |
| RXST | ▲ Buy | Open Market | 1,767 | $55K | 1/16/2025 | View on chart |
| RXST | ▲ Buy | Open Market | 1,443 | $45K | 1/15/2025 | View on chart |
| RXST | ▲ Buy | Open Market | 5,570 | $251K | 11/13/2024 | View on chart |
| RXST | ▲ Buy | Open Market | 4,090 | $184K | 11/13/2024 | View on chart |
| RXST | ▲ Buy | Open Market | 1,705 | $76K | 11/13/2024 | View on chart |
| RXST | ▲ Buy | Open Market | 11,111 | $504K | 11/12/2024 | View on chart |
| RXST | ▲ Buy | Grant | 2,554 | — | 6/6/2024 | View on chart |
| RXST | ▼ Sell | Gift | 7,083 | $0 | 2/5/2024 | View on chart |
| RXST | ▼ Sell | Gift | 7,083 | $0 | 2/5/2024 | View on chart |
| RXST | ▼ Sell | Gift | 46,884 | $0 | 2/5/2024 | View on chart |
| RXST | ▼ Sell | Gift | 46,884 | $0 | 2/5/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 2,000 | $90K | 1/8/2024 | View on chart |
| RXST | ▼ Sell | Open Market | 10,000 | $401K | 12/14/2023 | View on chart |
| RXST | ▼ Sell | Open Market | 2,000 | $80K | 12/14/2023 | View on chart |
| RXST | ▼ Sell | Other | 7,083 | $0 | 11/13/2023 | View on chart |
| RXST | ▼ Sell | Other | 7,083 | $0 | 11/13/2023 | View on chart |
| RXST | ▼ Sell | Other | 45,680 | $0 | 11/13/2023 | View on chart |
| RXST | ▼ Sell | Other | 81,450 | $0 | 11/13/2023 | View on chart |
| RXST | ▼ Sell | Other | 1,204 | $0 | 8/17/2023 | View on chart |
| RXST | ▼ Sell | Other | 81,450 | $0 | 8/17/2023 | View on chart |
| RXST | ▲ Buy | Grant | 5,731 | $0 | 6/1/2023 | View on chart |
| RXST | ▲ Buy | Grant | 10,349 | $0 | 6/2/2022 | View on chart |
| RXST | ▲ Buy | Open Market | 8,150 | $102K | 11/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds
Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds. Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.